UF1AG094587
Cooperative Agreement
Overview
Grant Description
DIGITAL HEALTH TECHNOLOGIES FOR MONITORING MOTOR FUNCTION IN PROGRESSIVE SUPRANUCLEAR PALSY AND DEMENTIA WITH LEWY BODIES - PROJECT SUMMARY PROGRESSIVE SUPRANUCLEAR PALSY (PSP) IS A SEVERE AND RAPIDLY PROGRESSIVE FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) SYNDROME THAT LACKS EFFECTIVE TREATMENT AND LEADS TO A RAPID ONSET OF DEMENTIA, DISABILITY, AND DEATH. DEMENTIA WITH LEWY BODIES (DLB) IS THE SECOND MOST COMMON TYPE OF NEURODEGENERATIVE DEMENTIA AFTER ALZHEIMER’S DISEASE. BOTH PSP AND DLB CAUSE SIGNIFICANT MOTOR IMPAIRMENT, RESULTING IN PROGRESSIVE LOSS OF INDEPENDENCE IN ACTIVITIES OF DAILY LIVING, SUCH AS EATING, DRESSING, AND WRITING. THERE ARE NO FDA-APPROVED TREATMENTS FOR FTLD SYNDROMES (INCLUDING PSP) OR DLB. ONE OF THE KEY CHALLENGES IN THE DEVELOPMENT OF NEW EFFECTIVE THERAPIES FOR DLB SYNDROMES IS THE LACK OF VALIDATED INSTRUMENTS AND BIOMARKERS TO MEASURE DISEASE SEVERITY, DISEASE PROGRESSION, AND THE EFFECT OF THERAPEUTIC INTERVENTIONS. SINCE 2019, BIOSENSICS, MASSACHUSETTS GENERAL HOSPITAL (MGH) AND JOHNS HOPKINS UNIVERSITY (JHU) HAVE PARTNERED TO DEVELOP A WEARABLE-BASED REMOTE MONITORING SOLUTION FOR FTLD SYNDROMES. THE SOLUTION USES PAMSYSTM, A PATENTED AND VALIDATED PENDANT SENSOR FOR MONITORING PHYSICAL ACTIVITY, POSTURE, AND WALKING PARAMETERS DURING ACTIVITIES OF DAILY LIVING. THROUGH A DIRECT PHASE II SBIR AWARD (R44AG080861) FROM THE NATIONAL INSTITUTE ON AGING, WE HAVE DEMONSTRATED THE FEASIBILITY OF USING PAMSYS FOR TRACKING AMBULATORY CHANGE IN PSP. IN THIS PROJECT, WE WILL EXTEND OUR WORK BY USING BOTH PAMSYS AND PAMSYS ULMTM WRIST SENSORS TO ENABLE COMPREHENSIVE MONITORING OF UPPER AND LOWER LIMB FUNCTION. PAMSYS ULM IS A PATENTED WRIST SENSOR SOLUTION FOR MONITORING GOAL-DIRECTED MOVEMENTS OF THE UPPER LIMB DURING ACTIVITIES OF DAILY LIVING. THE PRIMARY GOAL OF THE PROJECT IS TO QUALIFY DIGITAL MONITORING BIOMARKERS OF MOTOR FUNCTION FOR BOTH PSP AND DLB WITH THE FDA BIOMARKER QUALIFICATION PROGRAM (BQP). CONTEXT OF USE: COU1 AND COU2) MONITORING BY WORKING BIOMARKERS TO TRACK AMBULATORY CHANGE OVER TIME IN PSP AND DLB, COU3 AND COU4) MONITORING BIOMARKERS TO TRACK CHANGES IN UPPER LIMB FUNCTION OVER TIME IN PSP AND DLB. WE WILL WORK WITH CUREPSP, THE ASSOCIATION FOR FRONTOTEMPORAL DEMENTIA, AND THE LEWY BODY DEMENTIA ASSOCIATION TO RECRUIT STUDY PARTICIPANTS AND LEVERAGE AN NIH-FUNDED PLATFORM TRIAL IN PSP TO FACILITATE PATIENT RECRUITMENT AND ASSURE ENROLLMENT DIVERSITY. WE WILL DEMONSTRATE THE ACCURACY (ANALYTICAL VALIDATION) OF BOTH PAMSYS AND PAMSYS ULM IN PSP AND DLB. IN ADDITION, WE WILL CONDUCT A PROOF-OF-CONCEPT STUDY TO DEMONSTRATE THE FEASIBILITY AND RELIABILITY OF MONITORING MOTOR FUNCTION IN PSP AND DLB USING PAMSYS AND PAMSYS ULM. AFTERWARD, WE WILL CONDUCT A MULTISITE LONGITUDINAL CLINICAL VALIDATION OF DIGITAL HEALTH TECHNOLOGIES FOR MONITORING MOTOR FUNCTION IN A SIZEABLE AND DIVERSE COHORT OF PSP AND DLB PATIENTS AND COMPARE THIS TO FUNCTIONAL SCALES AND PATIENT-REPORTED OUTCOME MEASURES. MOREOVER, AS RECOMMENDED BY THE FDA BQP, WE WILL CONDUCT INTERVIEWS WITH ALL PARTICIPANTS USING THE TECHNOLOGY ACCEPTANCE MODEL TO EXAMINE THE PERCEPTION OF BENEFIT, TECHNOLOGY ACCEPTANCE AND ANXIETY, AND ATTITUDE TOWARD USE FROM PATIENTS’ POINT OF VIEW.
Awardee
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Massachusetts
United States
Geographic Scope
State-Wide
Biosensics was awarded
Digital Health Monitoring PSP DLB: Biomarker Qualification Program
Cooperative Agreement UF1AG094587
worth $5,174,076
from National Institute on Aging in September 2025 with work to be completed primarily in Massachusetts United States.
The grant
has a duration of 4 years and
was awarded through assistance program 93.866 Aging Research.
The Cooperative Agreement was awarded through grant opportunity Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
9/1/25
Start Date
8/31/29
End Date
Funding Split
$5.2M
Federal Obligation
$0.0
Non-Federal Obligation
$5.2M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
UF1AG094587
SAI Number
UF1AG094587-216788761
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
C9MRZK4B7K39
Awardee CAGE
4TN46
Performance District
MA-90
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Modified: 9/24/25